CAR-T Therapy Shows Promise in Lenalidomide-Refractory Multiple Myeloma
核心洞察
CARTITUDE-4 trial results show promise for patients with lenalidomide-refractory multiple myeloma (搜索) after 1-3 prior lines of therapy, indicating a potential new treatment option.
Five-year follow-up data from the TRANSCEND-NHL-001 trial were discussed, providing insights into the long-term efficacy and safety of CAR-T cell therapy in lymphoma (搜索).
Bendamustine was found to be an effective alternative to fludarabine for lymphodepletion in large B-cell lymphoma (搜索) patients receiving CD19 (搜索)-directed CAR-T therapy, addressing fludarabine shortages.
CAR-T therapy is showing promise in treating patients with lenalidomide-refractory multiple myeloma (搜索) (MM). The results come from patients with lenalidomide-refractory MM treated in the CARTITUDE-4 trial after 1 to 3 lines of prior therapy.
TRANSCEND-NHL-001 Trial Update
The clinical director of lymphoma (搜索) services at the University of Colorado discussed 5-year follow-up data from the TRANSCEND-NHL-001 clinical trial, offering insights into the long-term outcomes of CAR-T cell therapy in lymphoma patients.
Bendamustine as Fludarabine Alternative
In response to fludarabine shortages, research indicates that lymphodepletion with bendamustine is an effective alternative for patients with large B-cell lymphoma (搜索) undergoing CD19 (搜索)-directed CAR T-cell therapy. This finding provides a crucial option for clinicians facing drug supply challenges.
Exa-cel Data Update
The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute presented the latest data update from the CLIMB SCD-121 trial evaluating exa-cel, offering new insights into its efficacy and safety profile.
Tabelecleucel for EBV-Associated Lymphoproliferative Disease
With an FDA decision anticipated in January, tabelecleucel has demonstrated sustained safety and efficacy with extended follow-up in treating Epstein-Barr virus-associated post-transplant lymphoproliferative disease (搜索), reinforcing its potential as a therapeutic option.